BREVITAL SODIUM (methohexital sodium) by Pfizer is clinical pharmacology compared with thiamylal and thiopental, methohexital is at least twice as potent on a weight basis, and its duration of action is only about half as long. First approved in 1960.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
BREVITAL SODIUM (methohexital sodium) is a short-acting barbiturate anesthetic administered via intravenous, intramuscular, or rectal routes. It induces rapid sleep within 30 seconds (IV) to 15 minutes (rectal) and is approximately twice as potent as thiamylal and thiopental with half the duration of action. The drug is metabolized hepatically via demethylation and oxidation, with minimal fat depot accumulation, enabling rapid recovery and fewer cumulative effects than other barbiturate anesthetics.
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling contracting brand team resources and focus shift to generic transition planning.
CLINICAL PHARMACOLOGY Compared with thiamylal and thiopental, methohexital is at least twice as potent on a weight basis, and its duration of action is only about half as long. Although the metabolic fate of methohexital in the body is not clear, the drug does not appear to concentrate in fat…
Worked on BREVITAL SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on BREVITAL SODIUM offers limited growth potential given its LOE-approaching status and zero linked job openings, but provides valuable experience in generic transition management, regulatory compliance, and legacy product optimization. This role is best suited for professionals seeking expertise in pharmaceutical lifecycle management, cost containment, and defending mature market positions rather than innovation-focused career trajectories.